John Bel Edwards
GOVERNOR

**Dr. Courtney N. Phillips**
SECRETARY

State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: March 22, 2023

TO: All Louisiana Medicaid Prescribing Providers and Pharmacists

FROM: Tara A. LeBlanc, Medicaid Executive Director

SUBJECT: Louisiana Medicaid Pharmacy Point of Sale (POS) Edits-
April 2023

Effective April 1, 2023, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement new Point of Sale (POS) edits. The POS edits apply to pharmacy claims submitted to FFS and MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, and UnitedHealthcare).

Point of Sale Therapeutic Duplication of Xelstrym with Sunosi™ or Wakix®
Pharmacy claims for dextroamphetamine (Xelstrym™) will deny if there is an active claim on the recipient's file for solriamfetol (Sunosi™) or pitolisant (Wakix®) and vice versa.

Point of Sale Therapeutic Duplication of Xelstrym™ with Provigil or Nuvigil
Pharmacy claims for dextroamphetamine (Xelstrym™) will deny if there is an active claim on the recipient's file for modafinil (Provigil) or armodafinil (Nuvigil) and vice versa.

Point of Sale Therapeutic Duplication of Xelstrym™ with another Long-Acting Stimulant or Related Medication for ADHD
Pharmacy claims for dextroamphetamine (Xelstrym™) will deny if there is an active claim on the recipient's file for any other long-acting stimulant and related medication for ADHD and vice versa.

Pharmacy claims with a therapeutic duplication will deny with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to
EOB Code 482 (Therapeutic Duplication)

After consultation with the prescriber, the pharmacist may override the therapeutic duplication denial by submitting:

NCPDP 439-E4 field (Reason for Service Code) **TD** (Therapeutic Duplication)
NCPDP 440-E5 field (Professional Service Code) **MØ** (Prescriber Consulted)
NCPDP 441-E6 field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Point of Sale Edit for Drug-Drug Interaction of Tadalafil Suspension (Tadliq®) with Nitrates
Pharmacy claims for tadalafil suspension (Tadliq®) are monitored at the pharmacy POS for a drug-drug interaction with nitrates. Incoming prescriptions for tadalafil suspension (Tadliq®) will deny when the recipient has an active prescription for a nitrate. Incoming prescriptions for a nitrate will deny when the recipient has an active prescription for tadalafil suspension (Tadliq®).

Pharmacy claims with a drug-drug interaction will deny with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to
EOB code 471 (Drug-Drug Interaction)

After consultation with the prescriber, the pharmacist may override the drug-drug interaction denial by submitting:

NCPDP 439-E4 field (Reason for Service Code) **DD** (Drug-Drug Interaction)
NCPDP 440-E5 field (Professional Service Code) **MØ** (Prescriber Consulted)
NCPDP 441-E6 field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Point of Sale Anticonvulsant Prior Use Edit for Ganaxolone (Ztalmy®)
When a pharmacy claim is submitted for ganaxolone (Ztalmy®), the pharmacy POS system should verify **ONE** of the following in the previous 365-day period:

- Claims for **TWO** different anticonvulsant medications (**AT LEAST ONE** claim for each; may be preferred or non-preferred); **OR**
- **ONE** paid claim for ganaxolone (Ztalmy®).

If there is no evidence of prior use of ganaxolone (Ztalmy®) or two different anticonvulsant medications (brand or generic/preferred or non-preferred) within the previous 365 days, pharmacy claims submitted for ganaxolone (Ztalmy®) will reject at POS with the following:
MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to
        EOB code 214 (Prior Use Anticonvulsant).

Upon consultation with the prescriber to verify the necessity of the requested therapy, the pharmacist may override the denial by submitting the following override at POS:

NCPDP 439-E4 Field (Reason for Service Code) **PP** (Plan Protocol)
NCPDP 440-E5 Field (Professional Service Code) **MØ** (Prescriber Consulted)
NCPDP 441-E6 Field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Additional Information:
FFS Only: Most pharmacy claim denials can be overridden in emergency situations at Point of Sale. If it is necessary to override the claim, "**03**" can be entered in **NCPDP field 418-DI** (Level of Service). Refer to www.lamedicaid.com for the POS User Guide for drug specific override procedures.
MCO Only: If an override is required, or additional assistance needed, contact the health plan. (See contact information at the end of this document.)

Refer to http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf for the PDL, which is inclusive of the *Louisiana Uniform Prescription Drug Prior Authorization Form,* medication list, and criteria.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

Healthcare Provider	Pharmacy Help Desk	Pharmacy Help Desk Phone Number
Aetna	CVS Health	(855) 364-2977
AmeriHealth Caritas	PerformRx	(800) 684-5502
Fee for Service	Gainwell Technologies	(800) 648-0790
Healthy Blue	CVS	(833) 236-6194
Humana Healthy Horizons	Gainwell Technologies	(800) 648-0790
Louisiana Healthcare Connections	CVS Caremark	(800) 311-0543
UnitedHealthcare	Optum Rx	(866) 328-3108

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

TL/MBW/GJS

c: Healthy Louisiana Plans
          Melwyn B. Wendt
          Gainwell Technologies